80278-25-7

Usage

Uses

Used in Pharmaceutical Industry:
(Isoquinolin-5-yloxy)-acetic acid is used as a therapeutic agent for the treatment of various diseases such as cancer, autoimmune disorders, and viral infections. Its role as an inhibitor of dihydroorotate dehydrogenase makes it a potential candidate for targeting the de novo pyrimidine synthesis pathway, which is often upregulated in rapidly dividing cells like cancer cells.
Used in Antioxidant and Anti-Inflammatory Drug Development:
(Isoquinolin-5-yloxy)-acetic acid is utilized as a key component in the development of new drugs aimed at addressing oxidative stress and inflammatory conditions. Its antioxidant and anti-inflammatory properties suggest that it could be effective in mitigating the harmful effects of reactive oxygen species and reducing inflammation, which are common in a variety of pathological conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (isoquinolin-5-yloxy)-acetic acid serves as a valuable compound for research into the mechanisms of action of drugs targeting specific enzymes and pathways. Its structural features and biological activities make it a useful tool for designing and optimizing new pharmaceutical agents with improved efficacy and selectivity.

Upstream product

• 2439-04-5 5-hydroxyisoquinoline 
• 130292-81-8 methyl 5-isoquinolyloxyacetate 

Downstream Products

• 566939-11-5 (R)-2-[2-(Isoquinolin-5-yloxy)-acetylamino]-3-methylsulfanyl-propionic acid (1S,2S)-2-benzyloxycarbonylamino-1-((R)-4-tert-butylcarbamoyl-5,5-dimethyl-thiazolidine-3-carbonyl)-3-phenyl-propyl ester 
• 566939-12-6 (S)-2-[2-(Isoquinolin-5-yloxy)-acetylamino]-3-methyl-butyric acid (1S,2S)-2-benzyloxycarbonylamino-1-((R)-4-tert-butylcarbamoyl-5,5-dimethyl-thiazolidine-3-carbonyl)-3-phenyl-propyl ester 
• 566939-10-4 (S)-2-[2-(Isoquinolin-5-yloxy)-acetylamino]-pentanoic acid (1S,2S)-2-benzyloxycarbonylamino-1-((R)-4-tert-butylcarbamoyl-thiazolidine-3-carbonyl)-3-phenyl-propyl ester 
• 169752-80-1 (R)-2-[2-(Isoquinolin-5-yloxy)-acetylamino]-3-methylsulfanyl-propionic acid (1S,2S)-2-benzyloxycarbonylamino-1-((R)-4-tert-butylcarbamoyl-thiazolidine-3-carbonyl)-3-phenyl-propyl ester 
• 178986-90-8 (S)-2-[2-(Isoquinolin-5-yloxy)-acetylamino]-3-methyl-butyric acid (1S,2S)-2-benzyloxycarbonylamino-1-((R)-4-tert-butylcarbamoyl-thiazolidine-3-carbonyl)-3-phenyl-propyl ester 
• 147384-69-8 Kynostatin-227 
• 156880-90-9 (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[(S)-2-(5-isoquinolinyloxyacetyl)amino-3-methylbutanoyl]amino-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide 

Relevant academic research and scientific papers

β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors

β-Amino-α-hydroxycarboxylic acid derivatives represented by the following formula and salts thereof which are useful as human immunodeficiency virus (HIV) protease inhibitors: The compounds are effective for treating a patient suffering from AIDS and AIDS related diseases.

Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere

We designed and synthesized a new class of peptidomimetic human immunodeficiency virus protease inhibitors containing a unique unnatural amino acid, allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid], with a hydroxymethylcarbonyl isostere as the active moiety. From a structure-activity relationship study of HIV-1 protease inhibition, enzyme selectivity for other aspartyl proteases, the antiviral activity and pharmacokinetics in rats, 24c (KNI-227) and 24d (KNI-272, our first clinical candidate) were found to be selective and orally potent HIV protease inhibitors. Moreover, an improvement of the pharmacokinetic features of KNI-272 provided two long-lasting and highly bioavailable compounds (24g: JE-2178,h: JE-2179).